Items Tagged ‘copanlisib’

May 23, 2018

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.   Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), […]

View full entry

Tags: Aliqopa, CHRONOS-1 clinical study, copanlisib, follicular non-hodgkin lymphoma, News, Non-Hodgkin's Lymphoma, Precision Cancer Medicine


October 18, 2017

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” said Richard Pazdur, M.D., director of […]

View full entry

Tags: Aliqopa, copanlisib, Follicular Lymphoma, News, Non-Hodgkin's Lymphoma